AstraZeneca To Fund Rs 250 crore on expansion of its GCC in India

AstraZeneca India Private Limited (AZIPL), the British-Swedish drugmaker's global capabilities center (GCC), has announced a Rs 250 crore ($30 million) investment to expand its Global Innovation and Technology center (GITC) in...

Ipsen Expands Pact with Exelixis To Develop Cabometyx

Ipsen, a worldwide biopharmaceutical firm with an emphasis on getting groundbreaking medicines to patients in three remedial regions: oncology, interesting sickness and neuroscience, has reported confirmation of an extended partnership and license...

Bone Health Technologies Secures US Patent For Osteoboost

Bone Health Technologies (BHT), a leading medtech innovator developing breakthrough noninvasive and drug-free solutions for low bone density, announced the company has been awarded a fifth patent for Osteoboost—the first and only FDA-cleared...

EU Sanctions Sanofi's Dupixent For Smoker's lung's

Sanofi and Regeneron received European Union permission for the expanded use of their Dupixent injection in patients with chronic lung disease, a rare instance of the EU clearing a medicine faster than the United States. The EU Commission...

Sobi Commences Rolling BLA Application to US FDA For SEL-212

Sobi declared the commencement of a rolling Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for SEL-212. The pivotal studies DISSOLVE I and II served as the foundation for the submission. For the treatment of...

Kedrion Biopharma To Market Immunoglobulin therapy Yimmugo in US

Kedrion Biopharma Inc., a biopharmaceutical firm, declared that it has established the framework for a long-term partnership with Biotest AG for the complete commercialization and marketing of the immunoglobulin therapy Yimmugo in the United...

© 2024 India Pharma Outlook. All Rights Reserved.